default_top_notch
default_news_top
default_news_ad1
default_nd_ad1

GC surpasses 200-million mark in flu vaccine production

Lee Han-soo  Published 2019.05.03  14:39  Updated 2019.05.03 14:39

공유
default_news_ad2

GC has become the first local company to manufacture more than 200 million influenza vaccines.

Employees in GC’s factory in Hwasun, South Jeolla Province, celebrate the production of more than 200 million influenza vaccine, on Friday.

The number is significant as it means that over 200 million people around the world have received GC's flu vaccine. The company attained the 100-million mark for domestic use last year.

The company explained that such a feat was possible due to its fast advance into the global market. GC began exporting flu vaccines in 2010, a year after it launched the product in Korea. So far, the company has exported its product to 45 countries around the globe.

By expanding its export volume to Latin America, the company has managed to maintain its production system throughout the year. GC is the number one player in the flu vaccine bid by the Pan-American Health Organization (PAHO), one of the world's largest vaccine markets, for the past six consecutive years.

The company has recently secured an additional $35.7 million contract to supply flu vaccine to Latin America from PAHO.

"We are raising our competitiveness in both the domestic and foreign markets through our optimized production system," a company official said. "As the influenza vaccine develops in proportion to the production volume, the company will strengthen its position as a global vaccine manufacturer by tapping into new markets."

corea022@docdocdoc.co.kr

<© KBR , All rights reserved.>
default_news_ad5
default_news_bottom
default_nd_ad4
default_bottom
#top
default_bottom_notch